Phosphatidylinositol 4-kinase beta (PI4Kβ) (PI4Kβ)

Plasmodium phosphatidylinositol 4-kinase beta (PI4Kβ) is a critical lipid kinase essential for the survival and development of malaria-causing parasites across all stages of their life cycle, including the liver, asexual blood, and transmission stages (McNamara et al., 2013, Nature). It catalyzes the phosphorylation of phosphatidylinositol (PI) to generate phosphatidylinositol 4-phosphate (PI4P), a key signaling molecule and structural component required for membrane biogenesis and intracellular trafficking (Paquet et al., 2017, Journal of Medicinal Chemistry). In Plasmodium, PI4Kβ is localized to the Golgi apparatus and is vital for the formation of the parasitophorous vacuole membrane and the plasma membrane during schizogony (Vaidya et al., 2014, Trends in Parasitology). Inhibition of this enzyme leads to the depletion of PI4P, resulting in the failure of cytokinesis and the subsequent death of the parasite (Medicines for Malaria Venture, 2023). Due to its essentiality and the presence of distinct structural features compared to the human ortholog, PI4Kβ has emerged as a high-priority target for the development of next-generation antimalarial drugs (Bertschi et al., 2022, Nature Communications). Several small-molecule inhibitors, such as MMV390048 and UCT943, have demonstrated potent activity in clinical and preclinical studies, highlighting the target's potential for both treatment and prophylaxis (Van der Watt et al., 2018, Science Translational Medicine).

Other names

PI4KIIIβPI4KIIIbetaPfPI4KPvPI4KPhosphatidylinositol 4-kinase type III betaPlasmodium falciparum PI4K

ATP-competitive inhibition of the kinase activity, preventing the conversion of phosphatidylinositol to phosphatidylinositol 4-phosphate (PI4P), which disrupts membrane trafficking and parasite replication.